Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

3.810 -0.390 (-9.29%)
Streaming Delayed Price Updated: 1:49 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,220,395
Open 4.120
Bid (Size) 3.810 (1,000)
Ask (Size) 3.820 (300)
Prev. Close 4.200
Today's Range 3.700 - 4.148
52wk Range 1.110 - 6.370
Shares Outstanding 20,187,904
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting
Via Investor Brand Network
News headline image
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
From Annovis Bio Inc.
Via GlobeNewswire

Performance

YTD
-25.4%
-25.4%
1 Month
+91.5%
+91.5%
3 Month
+64.9%
+64.9%
6 Month
+36.1%
+36.1%
1 Year
-32.7%
-32.7%

More News

Read More
News headline image
Annovis Announces Two Presentations at the CTAD 2025 Conference
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia ↗
Via Stocktwits
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program
Via Investor Brand Network
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Via FinancialNewsMedia
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients ↗
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports New Data Showing Buntanetap Reverses Cognitive Decline in Parkinson’s Patients With Amyloid Co-Pathology
Via Investor Brand Network
News headline image
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
Topics Intellectual Property
News headline image
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
Via Investor Brand Network
News headline image
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces $3.4 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Annovis Bio, Inc. Common Stock publicly traded?
Yes, Annovis Bio, Inc. Common Stock is publicly traded.
What exchange does Annovis Bio, Inc. Common Stock trade on?
Annovis Bio, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Annovis Bio, Inc. Common Stock?
The ticker symbol for Annovis Bio, Inc. Common Stock is ANVS on the New York Stock Exchange
What is the current price of Annovis Bio, Inc. Common Stock?
The current price of Annovis Bio, Inc. Common Stock is 3.810
When was Annovis Bio, Inc. Common Stock last traded?
The last trade of Annovis Bio, Inc. Common Stock was at 12/11/25 01:49 PM ET
What is the market capitalization of Annovis Bio, Inc. Common Stock?
The market capitalization of Annovis Bio, Inc. Common Stock is 76.92M
How many shares of Annovis Bio, Inc. Common Stock are outstanding?
Annovis Bio, Inc. Common Stock has 77M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.